Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. on February 6, 2018. The report addresses Item 5.02 regarding the departure of directors or officers, election of directors, appointment of officers, and compensatory arrangements of certain officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation decisions.
Material Changes
On February 6, 2018, the Compensation Committee of the Board of Directors approved the following actions:
- Set a target bonus percentage of 60% for 2018 for Isaac Ciechanover, Chief Executive Officer.
- Authorized discretionary cash bonus payments for 2017 performance to the following Named Executive Officers:
| Name | Title | Bonus Amount |
|---|---|---|
| Isaac Ciechanover | Chief Executive Officer | $262,912 |
| Christopher Haqq | EVP, R&D and Chief Scientific Officer | $149,539 |
| Gad Soffer | EVP and Chief Strategy Officer | $127,725 |
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The report is limited to the disclosure of the approved bonus structure and payments.
Key Facts for Investor Verification
- Verify the total cash outflow of approximately $540,176 for the approved 2017 discretionary bonuses.
- Confirm the 60% target bonus percentage established for the CEO for the 2018 fiscal year.
- Note that the company is classified as an emerging growth company.